Agenus Inc. AGEN reported first-quarter 2017 loss of 18 cents per share (including non-cash expenses), narrower than the Zacks Consensus Estimate of a loss of 32 cents and the year-ago loss of 37 cents. The decline was due to the accelerated milestone payment received from Incyte Corporation INCY.
However, revenues were $26.96 million and surpassed the Zacks Consensus Estimate of $5 million. Revenues were considerably up from $5.96 million in the year-ago quarter.
Agenus’ share price decreased 1.0% year to date as against the Zacks classified Medical – Biomedical and Genetics industry’s gain of 4.7%.
Quarterly Highlights
Agenus’ fourth-quarter research and development (R&D) expenses were up 30.4% to $32.6 million. But general and administrative expenses were down 15.8% to $7.8 million.
Pipeline Update
Agenus is progressing well with the candidates in its pipeline. Currently, the company is evaluating AGEN1884 in a phase I study. It expects to report early safety and efficacy data on AGEN1884 at the upcoming ASCO conference in 2017.
Additionally, the company is evaluating INCAGN01876 in a phase I study for the treatment of solid tumors.
Notably, GlaxoSmithKline GSK filed for regulatory approval of Shingrix vaccine which contains Agenus’ QS-21 Stimulon. In fact, GSK’s shingles has been filed for regulatory approval in the US, Canada, the EU and also in Japan. The final position of the agency is expected in the second part of this year.
The company plans to initiate studies on anti-PD-1 antagonist AGEN2034 in the first half of 2017. Agenus also plans to begin combination studies on AGEN2034 and AGEN1884 in the second half of the year. Already, it has initiated phase I trial for AutoSynVax in Apr 2017 and completed enrolment as well.
Agenus Inc. Price, Consensus and EPS Surprise
Agenus Inc. Price, Consensus and EPS Surprise | Agenus Inc. Quote
Zacks Rank & Stocks to Consider
Agenus currently carries a Zacks Rank #3 (Hold). A top-ranked stock in the health care sector includes Galena Biopharma, Inc. GALE sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Galena’s loss per share estimates narrowed from $2.03 to 58 cents for 2017 over the last 60 days. The company posted positive earnings surprises in two of the four trailing quarters, with an average beat of 53.83%.
More Stock News: 8 Companies Verge on Apple-Like Run
Did you miss Apple’s 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.
A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
GlaxoSmithKline PLC (GSK): Free Stock Analysis Report
Galena Biopharma, Inc. (GALE): Free Stock Analysis Report
Agenus Inc. (AGEN): Free Stock Analysis Report
Infinity Pharmaceuticals, Inc. (INFI): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
May 05, 2017 at 11:03PM
from Zacks Equity Research
No comments:
Post a Comment